Key Highlights
- Eylea HD outsold legacy Eylea in the US for the first time, and the combined Franchise decline has slowed sharply, but the biosimilar wave has not yet arrived.
- Full repayment of the Sanofi Development Balance mechanically lifts collaboration Revenue from Q3 2026, independent of commercial execution.
- At 12.6 times forward Earnings with $17.8 billion of cash and a $3 billion buyback running, the stock is priced for erosion that Q2 did not show.
- Regeneron reported on 30 July that second-quarter revenue rose 17% to $4.29 billion and non-GAAP Earnings Per Share climbed 11% to $14.29.
A second straight quarter of double-digit growth
Regeneron ( Nasdaq :REGN) reported on 30 July that second-quarter revenue rose 17% to $4.29 billion and non-GAAP earnings per share climbed 11% to $14.29. Both comfortably cleared consensus of roughly $3.82 billion and $10.26, according to Reuters. Chief executive Leonard Schleifer described the quarter as delivering "double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio."
The more consequential detail sat one layer down. Eylea HD, the higher-dose, longer-interval version of the company's anti-VEGF eye drug, booked $596 million in US net sales, up 52% from $393 million, and outsold legacy Eylea for the first time. Legacy Eylea fell 45% to $412 million. Combined US franchise sales of $1.008 billion still trailed the $1.147 billion of a year earlier, but the mix has tilted decisively toward the asset with Patent life ahead of it. Eylea HD now represents roughly 60% of US franchise revenue, and management said physician unit Demand for it grew 24% sequentially following April's label extension to a 20-week dosing interval in wet AMD and diabetic macular edema.
What the market paid for
REGN closed at $762.63, up 3.29% on the day, following a 6.17% gain to $738.34 on results day itself. Together that is a roughly 9.7% two-session move, large for a $76 billion company and a sign that the sell side had been Underwriting the Eylea decline more aggressively than the offsetting engines. The shares have retraced much of the damage from a 52-week low of $541.00 but remain below the $821.11 high. Market Capitalization stands near $76.1 billion on about 99.9 million shares outstanding, per aggregated market data.
The engine that is actually doing the work
Dupixent, the IL-4/IL-13 antibody partnered with Sanofi, recorded $5.998 billion in global net sales in the quarter, 38% growth on a constant-currency basis, against a consensus figure Reuters put at $5.34 billion. The drug now treats more than 1.5 million patients across nine approved indications and, on Regeneron's own slides, is the most prescribed biologic among dermatologists, pulmonologists, allergists and ENT specialists. April brought another label extension: chronic spontaneous urticaria in children aged two to eleven.
Regeneron does not book Dupixent sales; Sanofi does. Regeneron takes roughly half the collaboration profit, and that line jumped 51% to $2.174 billion, with antibody profit share of $2.033 billion versus $1.282 billion. Crucially, the Sanofi Development Balance, an accumulated obligation of roughly $2.9 billion that Regeneron had been repaying out of its profit share, was fully extinguished at quarter-end. Management guided to a further step-up in collaboration revenue beginning in the third quarter. That is a genuine, mechanical earnings tailwind rather than an operating improvement, but it is real cash.
Libtayo, the PD-1 antibody Regeneron owns outright, added $489 million globally, up 30% ($343 million US, $146 million rest of world). Smaller launches contributed less: Evkeeza $53 million, Praluent $75 million, and the newly launched myeloma bispecific Lynozyfic just $17 million.
Reading the P&L
The headline masked some pressure. GAAP diluted EPS actually fell 5% to $12.23, and GAAP Net Income declined 7% to $1.297 billion, because GAAP gross Margin on product sales dropped to 78% from 83% and R&D rose 15% to $1.632 billion. Non-GAAP gross margin improved to 87%. Full-year guidance now calls for GAAP product gross margin of 78–79% and non-GAAP of 84–85%, with non-GAAP R&D of $5.95–6.05 billion and Capital Expenditure trimmed to $1.03–1.10 billion from $1.10–1.20 billion.
The Balance Sheet remains a fortress: $17.8 billion in cash and marketable securities against $1.99 billion of long-term Debt . First-half free Cash Flow was $1.42 billion on $1.89 billion of Operating Cash Flow , and the company repurchased $1.2 billion of stock in the quarter, $2.0 billion year to date, under a $3 billion authorization approved alongside first-quarter results. A $0.94 quarterly Dividend was declared in July.
Pipeline: breadth, with two visible dents
Regeneron counts roughly 50 clinical-stage candidates. Four late-stage priorities dominate: Lynozyfic, the cemdisiran complement franchise, Factor XI anticoagulant antibodies, and olatorepatide, a GIP/GLP-1 agonist for obesity heading into Phase 3 in the second half.
Cemdisiran is the nearest catalyst. FDA accepted the filing for anti-AChR-positive generalized myasthenia gravis under priority review with a November 2026 target action date, based on the Phase 3 NIMBLE trial. Dosed subcutaneously every 12 weeks and licensed worldwide from Alnylam, it would be the first siRNA approved in a disease affecting roughly 85,000 Americans. April also brought the Accelerated Approval of Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss, a scientific landmark that Regeneron is supplying free in the US, so it carries prestige rather than revenue.
The dents matter too. Itepekimab, the IL-33 antibody, met its primary endpoint in AERIFY-1 in COPD (27.1% exacerbation reduction on every-two-week dosing) but missed in AERIFY-2 (1.6%), and AstraZeneca's tozorakimab succeeded in both of its Phase 3s. A single positive trial is a thin regulatory basis. Separately, fianlimab failed to show statistically significant progression-free survival against pembrolizumab in first-line melanoma, closing off what had been a large opportunity for the LAG-3 antibody.
The bull and bear ledger
The bullish read is straightforward arithmetic. The Eylea drag is finite and shrinking as a share of the Business ; Dupixent's profit share is compounding at a rate that will soon dwarf it; the development-balance repayment adds margin from Q3 with no execution required; and Regeneron is buying back stock at a mid-teens multiple. RBC's Brian Abrahams noted the "marked commercial outperformance may help boost sentiment."
The bearish read starts with the fourth quarter. Amgen's Pavblu has been on the US market since late 2024, and settlements clear Alvotech/Teva, Sandoz, Formycon and Celltrion to launch aflibercept Biosimilars from Q4 2026. Management has already guided to low-to-mid-teens sequential demand declines in legacy Eylea. Roche's Vabysmo, at CHF 4.1 billion in 2025, continues to take share, and the branded intravitreal market itself contracted 15% last year. Dupixent's Economics are shared, not owned, and its 38% growth rate will decelerate. Beyond Dupixent, Regeneron has yet to prove it can build a second wholly owned blockbuster.
Valuation and what to watch
At $762.63 the shares trade at 18.9 times trailing earnings and 12.6 times forward, with a 4.9 price-to-sales ratio, EV/sales of 3.9 and EV/EBITDA of 14.0 on an Enterprise value of about $61 billion, a discount to large-cap pharma peers that reflects the Eylea overhang rather than the growth profile. The consensus price target sits near $833. Three things will settle the debate: how steeply legacy Eylea falls once biosimilars land in Q4, whether the promised collaboration-revenue step-up shows up in third-quarter margins, and the November cemdisiran decision.
Upcoming Catalysts
- Q3 2026 results, expected late October 2026. First quarter reflecting the Sanofi Development Balance step-up and the earliest biosimilar effects.
- Cemdisiran FDA decision, target action date November 2026. Priority review in generalized myasthenia gravis; would be the first siRNA approved in the disease.
- Aflibercept biosimilar launches, from Q4 2026. Alvotech/Teva, Sandoz, Formycon and Celltrion are cleared to enter the US market.
- Eylea HD prefilled syringe. Management is targeting approval before year-end after prior Manufacturing delays.
- Olatorepatide Phase 3 initiation, second half of 2026. Regeneron's entry into the obesity market.
Principal Risks
- Biosimilar cliff. Four aflibercept biosimilars are cleared to launch from Q4 2026 on top of Amgen's Pavblu, and management already expects low-to-mid-teens sequential demand declines in legacy Eylea.
- Anti-VEGF competition. Roche's Vabysmo remains the share gainer, and the US branded intravitreal market contracted 15% in 2025, shrinking the pool Eylea HD is fighting for.
- Concentration in a shared asset. Dupixent drives the growth but its profits are split with Sanofi and its sales are booked by Sanofi, limiting Regeneron's control over pricing and lifecycle strategy.
- Late-stage attrition. Itepekimab missed in one of two COPD Phase 3 trials and fianlimab failed in first-line melanoma, removing two large expected contributors.
- GAAP margin pressure. Product gross margin fell to 78% from 83% and R&D rose 15%, so GAAP earnings declined even as revenue grew 17%.
Conclusion
Eylea HD outsold legacy Eylea in the US for the first time, and the combined franchise decline has slowed sharply, but the biosimilar wave has not yet arrived. Set against that: Four aflibercept biosimilars are cleared to launch from Q4 2026 on top of Amgen's Pavblu, and management already expects low-to-mid-teens sequential demand declines in legacy Eylea. That tension shows up in the valuation: At 12.6 times forward earnings with $17.8 billion of cash and a $3 billion buyback running, the stock is priced for erosion that Q2 did not show. The next real test: First quarter reflecting the Sanofi Development Balance step-up and the earliest biosimilar effects.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...